Advertisement
UK markets close in 7 hours 27 minutes
  • FTSE 100

    8,208.16
    -44.75 (-0.54%)
     
  • FTSE 250

    21,111.10
    -91.79 (-0.43%)
     
  • AIM

    784.30
    -1.87 (-0.24%)
     
  • GBP/EUR

    1.1912
    +0.0009 (+0.07%)
     
  • GBP/USD

    1.2983
    -0.0006 (-0.05%)
     
  • Bitcoin GBP

    48,432.99
    +2,095.95 (+4.52%)
     
  • CMC Crypto 200

    1,310.77
    +41.82 (+3.29%)
     
  • S&P 500

    5,615.35
    +30.81 (+0.55%)
     
  • DOW

    40,000.90
    +247.10 (+0.62%)
     
  • CRUDE OIL

    82.02
    -0.19 (-0.23%)
     
  • GOLD FUTURES

    2,412.10
    -8.60 (-0.36%)
     
  • NIKKEI 225

    41,190.68
    -1,033.32 (-2.45%)
     
  • HANG SENG

    17,996.79
    -296.59 (-1.62%)
     
  • DAX

    18,703.44
    -44.74 (-0.24%)
     
  • CAC 40

    7,673.25
    -51.07 (-0.66%)
     

Celanese (CE) Inks Deal With Population Council for VitalDose

Celanese Corporation CE stated that it has agreed to supply its VitalDose Drug Delivery Platform to the Population Council for use in an innovative Multipurpose Prevention Technology (MPT) Intravaginal Ring (IVR). The IVR is currently in a phase 1b clinical trial designed to give contraception and HIV protection.

Long-acting continuous drug delivery dose forms, such as IVRs, pose fewer challenges to consistent use than oral forms that need daily doses. Providing benefits to patients, such as increased convenience, can lead to better results and is the driving force for the development of patient-centric dose forms.

For more than two decades, the VitalDose Drug Delivery Platform has been employed in patient-centric dose forms in women's health, providing customizable and consistent elution for a wide range of active pharmaceutical ingredient molecules.

The VitalDose Drug Delivery Platform has a long history of application in approved parenteral drug options in the United States, Europe and numerous other nations, providing reliable, controlled-release performance for a wide range of molecule types.

Shares of Celanese have gained 16.7% over the past year compared with a 12.7% rise of its industry.

Zacks Investment Research
Zacks Investment Research


Image Source: Zacks Investment Research

Celanese sees adjusted earnings in the range of $2-$2.50 per share for the third quarter of 2023. The projection includes the expected roughly 30 cents impact from the M&M amortization. Moreover, for the full year, Celanese anticipates adjusted earnings in the range of $9-$10, which includes approximately $1.20 per share of M&M transaction amortization.

Recognizing the volatility and unpredictability of the current market landscape and competitive environment, the company is proactively implementing strategic initiatives. These actions involve strengthening its commercial teams, aligning production and inventory levels with prevailing demand, implementing cost-saving measures and optimizing cash flow. These endeavors are anticipated to result in robust cash generation throughout 2023 and a continuation of earnings growth during the second half of the year.

Celanese Corporation Price and Consensus

Celanese Corporation price-consensus-chart | Celanese Corporation Quote

Zacks Rank & Key Picks

Celanese currently carries a Zacks Rank #5 (Strong Sell).

Better-ranked stocks in the basic materials space include Carpenter Technology Corporation CRS, The Andersons Inc. ANDE and Veritiv Corporation VRTV.

Carpenter Technology currently carries a Zacks Rank #1 (Strong Buy). The stock has rallied roughly 71.3% in the past year. CRS beat the Zacks Consensus Estimate in three of the last four quarters while meeting in one. It delivered a trailing four-quarter earnings surprise of 9.8%, on average. You can see the complete list of today’s Zacks #1 Rank stocks here.

Andersons currently carries a Zacks Rank #1. The stock has gained roughly 46.3% in the past year. ANDE beat the Zacks Consensus Estimate in each of the last four quarters. It delivered a trailing four-quarter earnings surprise of 64.4%, on average.

Veritiv currently carries a Zacks Rank #2 (Buy). The stock has rallied roughly 43.4% in the past year. VRTV beat the Zacks Consensus Estimate in three of the last four quarters. It delivered a trailing four-quarter earnings surprise of 6%, on average.

ADVERTISEMENT

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

The Andersons, Inc. (ANDE) : Free Stock Analysis Report

Carpenter Technology Corporation (CRS) : Free Stock Analysis Report

Celanese Corporation (CE) : Free Stock Analysis Report

Veritiv Corporation (VRTV) : Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research